PT  - JOURNAL ARTICLE
AU  - Iams, Wade T.
AU  - Lovly, Christine M.
TI  - Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived
AID  - 10.1158/2159-8290.CD-18-0489
DP  - 2018 Jul 01
TA  - Cancer Discovery
PG  - 797--799
VI  - 8
IP  - 7
4099  - http://cancerdiscovery.aacrjournals.org/content/8/7/797.short
4100  - http://cancerdiscovery.aacrjournals.org/content/8/7/797.full
SO  - Cancer Discov2018 Jul 01; 8
AB  - Summary: BLU-667 is a next-generation RET inhibitor that maximizes on-target and minimizes off-target effects. It is an exemplar of genotype-driven drug development followed by multi-histology basket trial validation that is becoming a paradigm for precision oncology. Cancer Discov; 8(7); 797–9. ©2018 AACR.See related article by Subbiah et al., p. 836.